Yan Huang

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Nan Chen, Wenfeng Fang, Jianhua Zhan et al. · Journal of Thoracic Oncology · 2015 · 686 citations · Full text

Medicine, Immunology, Oncology +17

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Li Zhang, Yan Huang, Shaodong Hong et al. · The Lancet · 2016 · 525 citations

Medicine, Oncology, Chemotherapy +11

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Wenfeng Fang, Yunpeng Yang, Yuxiang Ma et al. · The Lancet Oncology · 2018 · 507 citations

Medicine, Oncology, Pharmacology +13

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

Wenfeng Fang, Jianwei Zhang, Shaodong Hong et al. · Oncotarget · 2014 · 390 citations · Full text

Life Sciences, Cancer Biology, Oncology +16

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

Chun-ling Dai, Amit K. Tiwari, Chung‐Pu Wu et al. · Cancer Research · 2008 · 385 citations · Full text

Medicine, Oncology, Pharmacology +16